![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/17/2914885/20739/en/Ultragenyx-Announces-Successful-End-of-Phase-2-Meeting-with-FDA-for-GTX-102-Angelman-Syndrome-Program.html
https://www.fiercebiotech.com/biotech/ultragenyx-wins-surrogate-endpoint-debate-securing-green-light-seek-fda-approval-gene
https://www.fiercebiotech.com/biotech/ultragenyx-mereos-brittle-bone-drug-sustains-fracture-rate-cut-midphase-follow
https://www.globenewswire.com/news-release/2024/06/14/2898733/20739/en/Ultragenyx-Announces-Pricing-of-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html
https://www.globenewswire.com/news-release/2024/06/11/2897217/20739/en/Ultragenyx-and-Mereo-BioPharma-Announce-New-Phase-2-Data-from-Phase-2-3-Orbit-Study-Demonstrating-Sustained-Reductions-in-Fracture-Rates-Following-Treatment-with-Setrusumab-UX143-i.html
https://www.globenewswire.com/news-release/2024/06/04/2893424/20739/en/Ultragenyx-to-Participate-at-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/30/2891103/20739/en/Ultragenyx-Announces-Positive-Top-Line-Results-from-Phase-3-Study-of-DTX401-Gene-Therapy-for-Glycogen-Storage-Disease-Type-Ia-GSDIa.html
https://www.globenewswire.com/news-release/2024/05/17/2884488/20739/en/Ultragenyx-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/05/07/2877286/20739/en/Ultragenyx-to-Participate-at-Bank-of-America-s-2024-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/02/2874637/20739/en/Ultragenyx-Reports-First-Quarter-2024-Financial-Results-and-Corporate-Update.html